BC Innovations | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BC Week In Review | Jul 15, 2013
Company News

Bioventus LLC, Pfizer deal

Bioventus acquired an exclusive, worldwide license to Pfizer's bone morphogenetic protein (BMP) portfolio and associated IP. The portfolio includes a next-generation BMP in preclinical development and rights to recombinant human BMP 2 (rhBMP-2) in undisclosed...
BC Week In Review | Oct 4, 2010
Clinical News

Bosutinib: Development discontinued

Pfizer Inc. (NYSE:PFE), New York, N.Y.   Product: Bosutinib ( SKI-606 , PF-5208763 ); Celebrex celexcoxib ( YM177 , Celecox ); CP-533536 ( CP-533,536 ); dibotermin alfa ; figitumumab ( CP-751,871 , CP-751871 ); Lyrica pregabalin; PF-21780; PF-299685; PF-3512676 ( CpG7909 ); SU-14813;...
BioCentury | Jul 17, 2006
Strategy

Biologic rebirth

Compared to most of big pharma, the pharmaceutical company that is now Wyeth got a number of significant biotech assets relatively early on. But apart from driving some products already in development to market, it...
BC Week In Review | May 10, 2004
Clinical News

rhBMP-2/ACS recombinant protein bone graft substitute regulatory update

FDA granted marketing approval for rhBMP-2/ACS to treat acute, open tibia shaft fractures in adults. Medtronic Inc. (MDT, Minneapolis, Minn.) has worldwide rights to market the compound for the indication, and has marketing rights for...
BC Week In Review | Feb 10, 2003
Company News

Medtronic, Wyeth, Yamanouchi Pharmaceutical Co. sales and marketing update

MDT's Medtronic Sofamor Danek subsidiary will exclusively market in Europe WYE's and Yamanouchi's rhBMP-2/ACS recombinant protein bone graft substitute. The protein is marketed as InductOs to treat acute tibia fractures and as an adjunct to...
BC Week In Review | Sep 23, 2002
Clinical News

InductOs rhBMP-2/ACS recombinant protein treatment regulatory update

Europe granted marketing approval to the companies' InductOs rhBMP-2/ACS to treat acute tibia fractures in adults, and as an adjunct to open fracture reduction and intramedullary nail fixation. The companies plan to launch the product...
BC Week In Review | Jun 25, 2001
Clinical News

rhBMP-2/ACS recombinant protein treatment regulatory update

The FDA did not approve a PMA application for Wyeth-Ayerst's rhBMP-2/ACS recombinant protein treatment applied to an Absorbable Collagen Sponge matrix (ACS) for long-bone fractures. AHP division Wyeth-Ayerst, which said the letter cited concerns about...
BC Extra | Jun 22, 2001
Company News

AHP gets non-approvable letter for rhBMP-2/ACS

American Home Products said it received a non-approvable letter from the FDA for its PMA application for rhBMP-2/ACS , a recombinant protein treatment for use in long bone fractures. AHP said the letter cited concerns about...
BC Week In Review | Feb 26, 2001
Clinical News

rhBMP-2/ACS regulatory update

The FDA accepted for filing AHP's PMA for its rhBMP-2/ACS, a combination of recombinant human Bone Morphogenic Protein-2 (rhBMP-2) and Absorbable Collagen Sponge (ACS) matrix, to treat acute long-bone fractures that require open surgical management....
Items per page:
1 - 10 of 10